Navigation Links
Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12
Date:11/16/2011

SAN FRANCISCO, Nov. 16, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Cellmid Ltd. (ASX: CDY) (the "Company") and raised its twelve month target price to AUD $0.12. Ross Silver, Principal Analyst at Vista Partners stated, "Cellmid is on track to enter clinical trials for its AMI indication with a market estimated to be in the billions. The Company recently completed humanisation of its "first in class" anti-midkine antibody, hu91, in collaboration with Antitope Ltd. The humanisation has been completed on time and within budget and resulted in a drug that can enter clinical development. This is the most significant milestone to date in the Company's antibody program and has removed a substantial risk from the clinical development path." Mr. Silver continued, "Cellmid has a large portfolio of patents surrounding midkine and owns 21 patent families worldwide. Cellmid plans to monetize this portfolio through two segments: Diagnostics and Therapeutics. The Diagnostic programs are in a more advanced stage and are poised to face regulatory approvals first. The Therapeutic programs are in pre-clinical trials; however they involve high value antibody candidates with early partner/licensing potential."

To download a FREE copy of the Cellmid Ltd. research report, please visit www.vistapglobal.com and complete the research form to gain access to the report.  

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of
'/>"/>

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
3. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
7. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds ... ablation device market will expand through 2023 ... atrial fibrillation (AF). The increasing acceptance of ... AF will spur adoption of premium-priced products ... advanced loop diagnostic catheters, cryoablation catheters and ...
(Date:8/20/2014)... SALT LAKE CITY , Aug. 20, 2014 /PRNewswire/ ... their revolutionary mobile diagnostic platform during a special event ... City, Utah , on September 5, 2014. The ... be LiveStreamed on the ApolloDx website, www.apollodx.com .  ... will transform diagnostic testing," said Jared Bauer , ...
Breaking Medicine Technology:Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Oct. 15  Syndax Pharmaceuticals, Inc., a ... UK Intellectual Property Office allowed application GB0907347.9 ... covers the polymorph representing a preferred stable ... key claims covering the polymorph form B ...
... International, LLC today celebrates the official grand opening of its ... PA. The new facility not only preserves jobs in the ... staffing as the company grows. VWR is one ... with worldwide sales in excess of $3.5 billion, providing a ...
Cached Medicine Technology:Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat 2Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat 3VWR Opens New Global Headquarters in Radnor, PA 2VWR Opens New Global Headquarters in Radnor, PA 3
(Date:8/21/2014)... 21, 2014 Denver marketing agency ... for the American Lung Association in Colorado’s 2014 ... welcome Webolutions as a sponsor,” said Curt Huber, Chief ... Executive Director, American Lung Association in Colorado, “and we’re ... in this role they’ve defined.” , Webolutions has also ...
(Date:8/21/2014)... August 21, 2014 If chocolate is good ... will soon be very happy and healthy. Tracie is the ... Break ” contest. She and three of her coworkers will ... luxuriate at the world-famous Chocolate Spa® at The Hotel Hershey® ... third year working in the ambulatory surgery center at Connecticut ...
(Date:8/21/2014)... Rockville Centre, NY (PRWEB) August 21, 2014 ... injury law firm with over 25 years of experience ... dangerous prescription drugs and defective medical devices, announces the ... offer information to those women who believe they have ... The site offers valuable information about the severe adverse ...
(Date:8/21/2014)... Michael E. Steuer , local doctor ... to the Bluff City with recent philanthropy at local synagogue. ... the United States,” says friend and Rabbi David Julian of ... such as providing in-house for the needy and teaching Hebrew ... in the local synagogue. And to remain close with the ...
(Date:8/21/2014)... August 21, 2014 InSilico ... interventions and addressing the challenges of a ... OncoFinder, for signalome-wide pathway analysis. This ... cross-platform analysis of gene expression data obtained ... published in the journal Frontiers in Molecular ...
Breaking Medicine News(10 mins):Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:Connecticut Nurse Wins a Sweet Prize from California Casualty 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... INDIANAPOLIS, Sept. 14 In conjunction with today,s announcement ... to patients, Eli Lilly and Company (NYSE: ... Center of Excellence and its five business units: oncology, ... These leaders will provide improved line of sight to ...
... in dementia care is not so much related to equipment ... communication problems and misunderstandings. This is shown in a new ... Sweden. Dementia not only affects the memory and other ... to walk. ,The symptoms of dementia are very individual ...
... , AHIP to leverage MedAssurant,s datasets and ... affordability of healthcare. , , WASHINGTON, ... Inc., announced today that MedAssurant, through its healthcare data analytics ... quality and effectiveness of treatments. , , ...
... boosting the odds, experts say, , MONDAY, Sept. 14 (HealthDay ... the odds that a child will develop asthma or allergies, ... spent more than 1,000 hours swimming in chlorinated pools, either ... of having asthma than did teens who primarily swam in ...
... , , NCCN is ... forum to discuss the regulatory and operational aspects of research ... improvements can be made. Scheduled for October 26 - 27 ... and panel discussions on topics that challenge the conduct of ...
... Schizophrenia is a major public health problem. Affecting almost ... economic and social toll in addition to the distress, ... disease. Elements of the disease are present from birth, ... becomes fully expressed in early adulthood with long-lasting implications ...
Cached Medicine News:Health News:Lilly Names New Business Leaders 2Health News:Lilly Names New Business Leaders 3Health News:Lilly Names New Business Leaders 4Health News:Lilly Names New Business Leaders 5Health News:Lilly Names New Business Leaders 6Health News:Lilly Names New Business Leaders 7Health News:Lilly Names New Business Leaders 8Health News:Communication problems in dementia care cause physical strain 2Health News:MedAssurant to Support AHIP's Research Capabilities 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 3Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:The future of schizophrenia 2Health News:The future of schizophrenia 3Health News:The future of schizophrenia 4Health News:The future of schizophrenia 5
... was designed with thinner, long jaws ... IOL through a tunnel or clear ... the lens securely, but will not ... wide enough to allow the lens ...
Titanium. Curved 18 mm shafts with 1.5 wide grasping tip. Flat, serrated cross action handle with dull finish....
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
Excellent for inserting rigid or flexible implants. Rounded tips provide excellent purchase of the optic...
Medicine Products: